Breaking News Erdosteine has been positively tested as part of COVID-19 treatment
Recipharm is pleased to announce that the results of the study with Erdosteine as add-on treatment for COVID-19 patients are now available
The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region mostly affected by SARS-CoV-2.
The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID-19.
Full study outcomes have been recently published on the peer-reviewed journal Multidisciplinary Respiratory Medicine (Vol. 15, 2020, 713; https://mrmjournal.org/mrm/article/view/713).
This study opens up new perspectives for the use of Erdosteine in COVID-19 patients, most likely due to its multiple mechanism of action (antioxidant, mucoactive, anti-inflammatory, antibiotic enhancer) and its ability to increase the endogenous levels of Glutathione. This may have blocked the spreading of the virus in the lungs giving a faster recovery to patients treated.
Erdosteine was discovered and developed in Italy at Recipharm’s facility in Paderno Dugnano and is indicated for the treatment of acute and chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD).
Katherine Salessi Nia, Medical Manager for Erdosteine at Recipharm, commented: ”We have now been able to confirm the beneficial effects of Erdosteine in restoring the pulmonary functions also in patients affected by COVID-19. We are planning to develop further studies to investigate if the molecule can have a role in prophylaxis for this pandemic treatment”.
Erdosteine is Edmond Pharma's most successful Molecule, produced both in API and finished product forms, totally developed in house with Edmond research. Today it is marketed in nearly 40 countries worldwide.
Erdosteine is a mucolitic and it has a clinical efficacy in acute respiratory disease and in COPD with an unique mechanism of action.
The Erdosteine molecule is characterised by the presence of two sulphur atoms: one in the aliphatic side chain and the second enclosed in the heterocyclic ring (thiolactone). With these two blocked thiol groups, Erdosteine is an inactive pro-drug. Following first-pass metabolism, the opening of the thiolactone ring and desacetylation of the aliphatic side chain liberates free SH groups, with the formation of the active metabolite I, N-thiodiglycolylhomocysteine (Metabolite I), so, Erdosteine has no direct effect on gastric mucus.
Co-administration of antibiotics do not interfere to the action of the drug, unlike other compounds with similar therapeutic indications. Clinical findings also demonstrate that Erdosteine has good gastric tolerability after oral administration, and do not cause reflux phenomena like others thiols.
Compounds containing thiol groups often have an unpleasant smell and after intake may frequently cause reflux phenomena. These problems do not occur with Erdosteine.
The unique chemical structure of Erdosteine results in a compound that has multiple properties that are relevant to the treatment of chronic bronchitis, namely:
- muco-modulatory activity
- antibacterial adhesivity – infection prevention
- anti-inflammatory activity
- antioxidant activity
- potentiation (in vivo) of antibiotic therapy in respiratory infections
the present that anticipates the future
Modern life history had two big economical accelerators who boosted the quality and the quantity of life: coal and oil. Indeed, the growth of the industrial civilization is mentioned as “coal age” and the contemporary age as the “oil age".
Both these “ages” had as side effect to significantly increase environmental and specially the air pollution. It’s in the coal age that the word “smog” has been coined, and nowadays the quality of air is measured with the quality and the quantity of the micro-particles (PM10 etc). All the major agencies of the ambience (as other agencies in the world) gives maps of density of pollutants.
Man does not adapt himself to the change in the quality of the air and this is has led to of a lot of pathologies, not only of the respiratory tract. Scientific and politic world meet to confirm the impact of this “cost of the civilization”, and they send out serveral guidelines. These rules are made both to prevent the rise of respiratory diseases and to suggest several treatment.
As the epidemiologial importance of these disease (COPD will be the third cause of death in the world in 2030), research of new drugs or of a better use of known active principles, (back to the future) is one of the most important frontiers of pharmacological R&D. Edmond Pharma, heavily involved in respiratory R&D, opens this site in order to promote (accordingly to the laws about the communication to the patients) the diffusion of knowledge on these items with a focus on the updates.